Where do we stand with hepatoblastoma? A review

J.M. Schnater, S.E. Köhler, W.H. Lamers, D. von Schweinitz, D.C. Aronson*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Where do we stand with hepatoblastoma? A review.

Schnater JM, Kohler SE, Lamers WH, von Schweinitz D, Aronson DC.

Pediatric Surgical Center of Amsterdam, Emma Children's Hospital AMC, Academic Medical Center, Amsterdam, The Netherlands.

Hepatoblastoma (HB) is the most common pediatric liver malignancy, comprising approximately 1% of all pediatric cancers. The disparate clinical staging systems and histologic classifications that were developed during the last decades, nevertheless, reflect the remaining difficulties and uncertainties in characterizing HB. Furthermore, the combination of surgery and (neo)adjuvant chemotherapy has improved patient outcomes dramatically. A poor prognosis is associated with large tumor size, multifocality, extrahepatic disease, and metastatic spread. The exact etiology of HB remains unknown, but the cytogenetic alterations, phenotypic features, and biologic aspects that accompany this neoplasm yield more and more insight into its pathogenesis. New cell-biologic and molecular-biologic insights may lead to the development of new treatment modalities, especially for patients with a bad prognosis. This review summarizes the different aspects of this intriguing tumor and discusses the current status of research and treatment for patients with HB. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11585
Original languageEnglish
Pages (from-to)668-678
Issue number4
Publication statusPublished - 1 Jan 2003

Cite this